Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3

Immunology

Volumn 118, Issue 3, 2006, Pages 321-332

  Romano, Marta ^a   Roupie, Virginie ^a   Wang, Xiao M ^a   Denis, Olivier ^a   Jurion, Fabienne ^a   Adnet, Pierre Yves ^a   Laali, Rachid ^a   Huygen, Kris ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Ag85A; DNA vaccines; PstS 3; Tuberculosis

Indexed keywords

AG85A ANTIGEN; ANTIGEN; BCG VACCINE; CD8 ANTIGEN; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOLYL TRANSFERASE; PLASMID VECTOR; PROTEIN PSTS 3; RECEPTOR; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUBERCULOSIS;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIAL PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CRICETINAE; FEMALE; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; RECOMBINANT FUSION PROTEINS; TH1 CELLS; TRANSFECTION; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 33745219834     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02373.x     Document Type: Article

References (55)

1. Rook GA Dheda K Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 2005 5 : 661 7.
2. Colditz GA Brewer TF Berkey CS Wilson ME Burdick E. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994 271 : 689 702.
3. Colditz GA Berkey CS Mosteller F Brewer TF Wilson ME Burdick E Fineberg HV. The efficacy of bacillus Calmette-Guèrin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995 96 : 29 35.
4. Sonnenberg P Glynn JR Fielding K Murray J Godfrey-Faussett P Shearer S. How soon after infection with HIV does risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005 191 : 150 8.
5. Tiruviluamala P Reichman LG. Tuberculosis. Annu Rev Public Health 2002 23 : 403 26.
6. Orme IM McMurray DN Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001 9 : 115 8.
7. Huygen K. Minireview. On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect. Immun 2003, 71, 1613 21.
8. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994 62 : 2536 44.
9. Pal PG Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992 60 : 4781 92.
10. Ronning DR Klabunde T Besra GS Vissa VD Belisle J Sacchettini JC. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol 2000 7 : 141 6.
11. Wiker HG Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992 56 : 648 61.
12. Launois P DeLeys R N'Diaye Niang M et al. T cell epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 1994 62 : 3679 87.
13. Huygen K Abramowicz D Vandenbussche P et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun 1992 60 : 2880 6.
14. Huygen K Van Vooren J-P Turneer M Bosmans R Dierckx P De Bruyn J. Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand J Immunol 1988 27 : 187 94.
15. Launois P Huygen K De Bruyn J N'Diaye M Diouf B. Sarthou JL Grimaud J Millan J. T cell response to purified filtrate antigen 85 from Mycobacterium bovis bacillus Calmette-Guérin (BCG) in leprosy patients. Clin Exp Immunol 1991 86 : 286 90.
16. Huygen K Content J Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996 2 : 893 8.
17. Kamath AT Feng CG MacDonald M Briscoe H Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of M. tuberculosis. Infect Immun 1999 67 : 1702 7.
18. Baldwin SL D'Souza CD Orme IM et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tubercle Lung Dis 1999 79 : 251 9.
19. Feng CG Palendira U Demangel C Spratt JM Malin AS Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis BCG against tuberculosis. Infect Immun 2001 69 : 4174 6.
20. Romano M D'Souza S Adnet P-Y Laali R Jurion F Palfliet K Huygen K. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006 24 : 3353 3361.
21. Brooks JV Frank AA Keen MA Belisle JT Orme IM. Boosting vaccine for tuberculosis. Infect Immun 2001 69 : 2714 7.
22. Tanghe A D'Souza S Rosseels V Denis O Ottenhoff THM Dalemans W Wheeler C Huygen K. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001 69 : 3041 7.
23. Goonetilleke NP McShane H Hannan CM Anderson RJ Brookes R Hill AVS. Enhanced immunogenicity and protective efficacy againsy Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinanat modified vaccinia virus Ankara. J Immunol 2003 171 : 1602 9.
24. Williams AG Hatch J Clark SO, et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 2005 85 : 29 38.
25. McShane H Pathan AA Sander C Keating SM Gilbert SC Huygen K Fletcher HA Hill AVS. Recombinant modified vaccinia Ankara expressing antigen 85A boosts BCG-primed and naturally acquired anti-mycobacterial immunity in humans. Nat Med 2004 10 : 1240.
26. Huygen K Drowart A Harboe M ten Berg R Cogniaux J Van Vooren JP. Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG. Infect Immun 1993 61 : 2687 93.
27. Lefèvre P Braibant M De Wit L et al. Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG. J Bacteriol 1997 179 : 2900 6.
28. Tanghe A Lefèvre P Denis O et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999 162 : 1113 9.
29. + T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998 66 : 1527 33.
30. D'Souza S Rosseels V Romano M et al. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B and Ag85C from M tuberculosis. Infect Immun 2003 71 : 483 93.
31. b restricted cytolytic T cell activity against a putative phosphate transport receptor of M. tuberculosis. J Immunol 2004 172 : 6913 21.
32. De Groot AS McMurry J Marcon L Franco J Rivera D Kutzler M Weiner D Martin B. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005 23 : 2121 31.
33. Langermans JAM Doherty TM Vervenne RAW et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005 23 : 2740 50.
34. Skeiky YAW Alderson MR Ovendale P et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004 172 : 7618 28.
35. Dietrich J Aagaard C Leah R Olsen AW Stryhn A Doherty TM Andersen P. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine. Efficient protection and ESAT6-based sensitive monitoring vaccine efficacy. J Immunol 2005 174 : 6332 9.
36. van Pinxteren LAH Cassidy JP Smedegaard BHC Agger EM Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000 30 : 3689 98.
37. Flynn JL Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001 19 : 93 129.
38. Huygen K Lozes E Gilles B et al. Mapping of Th1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect Immun 1994 62 : 363 70.
39. Ruth N Mainil J Roupie V Frere J-M Galleni M Huygen K. DNA vaccination for the priming of neutralizing antibodies against non-immunogenic STa enterotoxin from enterotoxigenic Escherichia coli. Vaccine 2005 23 : 3618 27.
40. Snewin VA Gares M-P Gaora PO Hasan Z Brown I Young DB. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 1999 67 : 4586 93.
41. D'Souza S Rosseels V Denis O et al. Improved Tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002 70 : 3681 8.
42. Burton J Bamford R Peters C et al. A lymphokine, provisionally designated interleukin t and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994 91 : 4935 9.
43. + T cells, in mice vaccinated with DNA encoding Ag85A. Eur J Immunol 2000 30 : 2455 9.
44. Liu MA. DNA vaccines: a review. J Intern Med 2003 253 : 402 10.
45. Huygen K. Plasmid DNA vaccination. Microbes Infection 2005 7 : 932 8.
46. Braibant M Lefèvre P De Wit L Wattiez R Content J. Identification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporter. FEBS Lett 1996 394 : 206 12.
47. Rengarajan J Bloom BR Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci USA 2005 102 : 8327 32.
48. Derrick SC Li Yang A Morris SL. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004 23 : 780 8.
49. Schneider SC Ohmen J Fosdick L Gladstone B Guo J Ametani A Sercarz EE Deng H. Cutting edge: Introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T cell determinant display. J Immunol 2000 165 : 20 3.
50. + T cells cross-compete for MHC class II restricted peptide antigen complexes on the surface of antigen presenting cells. Immunol Cell Biol 2004 82 : 103 11.
51. Rosseels V Marche S Roupie V Govaerts M Godfroid J Walravens K Huygen K. Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. Infect Immun 2006 74 : 202 12.
52. Orme IM. The use of animal models to guide rational vaccine design. Microbes Infection 2005 7 : 905 10.
53. Romano M Roupie V Hamard M Huygen K. Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosis. Vaccine 2005 Epub ahead of print.
54. North RJ Jung Y-J. Immunity to tuberculosis. Annu Rev Immunol 2004 22 : 599 623.
55. Ha SJ Jeon B-Y Youn J-I Kim S-C Cho S-N Sung Y-C. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005 12 : 634 8.